Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals
MISSISSAUGA, ON, Nov. 3, 2014 /CNW/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it plans to commence a Phase 3 clinical study of Pennsaid 2% for the treatment of acute pain to support regulatory approval applications for Pennsaid 2% in international jurisdictions. The study will be conducted in Germany to assess the efficacy of Pennsaid 2% for the relief of pain associated with acute, localized muscle or joint injuries such as sprains, strains or sports injuries. Commencement of the study, which is subject to German regulatory approval, is expected in Q2 2015 with top-line results expected Q4 2015. The study will cost approximately CDN$1.5 million. Click